Clinical Trial Update: Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study of the Lyme borreliosis vaccine candidate VLA15 in a healthy pediatric and adult population, with results posted in June 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Borreliosis

Drugs mentioned

• VLA15

Snippet

Sponsor: Pfizer | Conditions: Lyme Borreliosis | Phase 2 | Status: COMPLETED | Results posted: 2023-06-07